Organon & Co. (NYSE:OGN) Shares Sold by Gilman Hill Asset Management LLC

Gilman Hill Asset Management LLC lowered its holdings in Organon & Co. (NYSE:OGN) by 3.4% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 628,663 shares of the company’s stock after selling 22,186 shares during the quarter. Organon & Co. accounts for about 1.6% of Gilman Hill Asset Management LLC’s investment portfolio, making the stock its 10th largest position. Gilman Hill Asset Management LLC owned about 0.24% of Organon & Co. worth $9,380,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. HB Wealth Management LLC grew its stake in shares of Organon & Co. by 64.2% in the fourth quarter. HB Wealth Management LLC now owns 18,114 shares of the company’s stock worth $270,000 after acquiring an additional 7,081 shares during the last quarter. Retireful LLC bought a new position in shares of Organon & Co. during the 4th quarter worth about $187,000. Quad Cities Investment Group LLC raised its position in shares of Organon & Co. by 37.5% during the fourth quarter. Quad Cities Investment Group LLC now owns 15,211 shares of the company’s stock valued at $227,000 after buying an additional 4,146 shares during the last quarter. 180 Wealth Advisors LLC raised its position in shares of Organon & Co. by 40.1% during the fourth quarter. 180 Wealth Advisors LLC now owns 58,293 shares of the company’s stock valued at $870,000 after buying an additional 16,697 shares during the last quarter. Finally, Horizon Bancorp Inc. IN lifted its stake in shares of Organon & Co. by 2,401.5% in the fourth quarter. Horizon Bancorp Inc. IN now owns 1,651 shares of the company’s stock valued at $25,000 after buying an additional 1,585 shares during the period. 77.43% of the stock is owned by institutional investors.

Organon & Co. Price Performance

NYSE:OGN opened at $15.77 on Monday. The company has a debt-to-equity ratio of 17.73, a quick ratio of 1.21 and a current ratio of 1.70. The company has a 50-day moving average of $15.32 and a 200-day moving average of $18.21. Organon & Co. has a 52 week low of $13.87 and a 52 week high of $23.10. The company has a market capitalization of $4.06 billion, a price-to-earnings ratio of 3.13, a PEG ratio of 0.86 and a beta of 0.76.

Organon & Co. (NYSE:OGN) last announced its quarterly earnings results on Thursday, October 31st. The company reported $0.87 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by ($0.03). Organon & Co. had a return on equity of 644.70% and a net margin of 20.30%. The business had revenue of $1.58 billion for the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter in the prior year, the business earned $0.78 EPS. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. As a group, equities research analysts anticipate that Organon & Co. will post 3.89 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Tuesday, November 12th were paid a dividend of $0.28 per share. The ex-dividend date was Tuesday, November 12th. This represents a $1.12 annualized dividend and a yield of 7.10%. Organon & Co.’s dividend payout ratio is currently 22.22%.

Analysts Set New Price Targets

Separately, TD Cowen raised Organon & Co. to a “hold” rating in a report on Wednesday, January 15th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Organon & Co. currently has a consensus rating of “Hold” and an average price target of $21.33.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.